Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 718 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Controlled Hypertension Clear all
Completed Not applicable Interventional

Health Literacy-Focused Program to Improve Blood Pressure Control in Korean Americans

NCT00406614
View directory record Official record
Conditions
Hypertension
Interventions
Health Literacy-Focused High Blood Pressure Intervention
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
60 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Ellicott City, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Phase 2 Interventional

Tadalafil in Subjects With Mild to Moderate Hypertension

NCT00157326
View directory record Official record
Conditions
Hypertension
Interventions
tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Oct 24, 2007 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Not applicable Interventional Results available

Achieving Blood Pressure Control Through Enhanced Discharge

NCT02069015
View directory record Official record
Conditions
Hypertension
Interventions
Patient education
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 11, 2026, 2:12 AM EDT
Recruiting Not applicable Interventional

Improving Hypertension Control in Safety-Net Settings: The Boston Hypertension Equity Alliance in Treatment

NCT06948838
View directory record Official record
Conditions
Hypertension, Hypertension Complicated
Interventions
RBPM, MII
Behavioral · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
16,895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Boston, Massachusetts • Quincy, Massachusetts • Roslindale, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Individually Tailored Web-Based Program to Improve Blood Pressure Control

NCT00377208
View directory record Official record
Conditions
Hypertension
Interventions
Web-Based Intervention
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Not applicable Interventional

Clinician Counseling and Cultural Competency to Improve Hypertension Control and Therapy Adherence

NCT00201149
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension
Interventions
Patient-centered Counseling
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 100 Years
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Phase 4 Interventional

A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension

NCT00058929
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
treprostinil sodium
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
8
States / cities
Los Angeles, California • Torrance, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 11, 2026, 2:12 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Vitamin D and Blood Pressure

NCT00459563
View directory record Official record
Conditions
Hypertension
Interventions
Vitamin D, calcitriol, Placebo
Drug
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Phase 2 Interventional

Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

NCT00847899
View directory record Official record
Conditions
Hypertension, Impaired Glucose Tolerance
Interventions
AR9281, Placebo
Drug
Lead sponsor
Arete Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
30
States / cities
Mobile, Alabama • Muscle Shoals, Alabama • Anaheim, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2009 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

NCT00635232
View directory record Official record
Conditions
Hypertension
Interventions
irbesartan, placebo, PS433540
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
40
States / cities
Pell City, Alabama • Tempe, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Sep 11, 2026, 2:12 AM EDT
Recruiting Not applicable Interventional

Evaluating Whether Treating Elevated Blood Pressure in the Inpatient Setting Impacts Patient Outcomes

NCT07208669
View directory record Official record
Conditions
Blood Pressure Control
Interventions
ACT-BP Intervention
Other
Lead sponsor
Elizabeth Pfoh
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Cleveland, Ohio • Mayfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.

NCT00250562
View directory record Official record
Conditions
Hypertension
Interventions
valsartan plus hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 11, 2026, 2:12 AM EDT
Completed No phase listed Observational

The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study

NCT00071903
View directory record Official record
Conditions
Pseudotumor Cerebri, Cystinosis
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 11, 2026, 2:12 AM EDT
Completed No phase listed Observational

Assessing Blood Pressure Remotely in Childhood Cancer Survivors

NCT02476162
View directory record Official record
Conditions
Hypertension
Interventions
iHealth Wireless Blood Pressure Monitor
Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 11, 2026, 2:12 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Randomized Controlled Pilot Trial of DASH Feeding in Older Low Socioeconomic Adults Without Heart Failure

NCT04113291
View directory record Official record
Conditions
Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
DASH Diet, Usual diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 74 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

NCT00758524
View directory record Official record
Conditions
Essential Hypertension
Interventions
LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

NCT00572455
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose, PF-04217329 - High Middle Dose, PF-04217329 - High Dose, PF-4217329 - Highest Dose, PF-04217329 - Vehicle, Latanoprost Vehicle, Latanoprost 0.005%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
23
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Results available

Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension

NCT04790279
View directory record Official record
Conditions
Hypertension in Pregnancy
Interventions
Amlodipine, NIFEdipine ER
Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older · Female only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

NCT04936035
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, ALN-AGT01
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
54
States / cities
Birmingham, Alabama • Tempe, Arizona • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients

NCT00675987
View directory record Official record
Conditions
Obesity, Hypertension, Hyperglycemia
Interventions
losartan, Placebo control
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Little Rock, Arkansas • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 11, 2026, 2:12 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

NCT07285655
View directory record Official record
Conditions
Pulmonary Hypertension Due to Lung Disease (Disorder)
Interventions
L606, Placebo
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

NCT01106014
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
43
States / cities
Mobile, Alabama • Tucson, Arizona • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

NCT06034743
View directory record Official record
Conditions
Uncontrolled Hypertension, Resistant Hypertension
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
43
States / cities
Saraland, Alabama • Scottsdale, Arizona • Sun City West, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 11, 2026, 2:12 AM EDT
Completed Phase 1 Interventional

Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

NCT01670266
View directory record Official record
Conditions
Ocular Hypertension (OHT), Mild Open Angle-glaucoma (OAG)
Interventions
ONO-9054, Placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
3
States / cities
Costa Mesa, California • Newport Beach, California • Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 11, 2026, 2:12 AM EDT